China's bio-targeted drug development has reached a new level

Kidney transplantation is the best treatment option for the treatment of end-stage renal disease, and the application of immunosuppressive agents is of crucial importance in kidney transplantation. After adding blenicopril to the basic immunosuppressive regimen, the incidence of acute rejection was reduced by 43.7% at 3 months after renal transplantation, and the incidence of acute rejection at 6 months was reduced by 40.2%; the patient's 1-year renal survival rate was 100%. %, 99.46%.

Recently, Jianniipei (common name: recombinant anti-CD25 humanized monoclonal antibody injection) independently developed by Shanghai CITIC Guojian Pharmaceutical Co., Ltd. was officially launched in the country. As an inducement drug, its highly humanized design minimizes the adverse effects of the drug and adds a strong insurance for the valuable organ source of kidney transplant patients. At the same time, the listing of this product also marks a new level in the development of China's bio-targeted drugs.

Kidney transplantation is the best treatment option for the treatment of end-stage renal disease, and the application of immunosuppressive agents is of crucial importance in kidney transplantation. In recent years, choosing a reasonable immunosuppressive regimen to prevent "immune suppression" and "immune suppression", improve the long-term survival of kidney transplanters and reduce the toxicity of long-term application of immunosuppressive agents has become a new trend.

Professor Tian Ye, director of urology at Beijing Friendship Hospital, Capital Medical University, director of the Urology Institute of Beijing Municipal Health Bureau and member of the Organ Transplantation Committee of the Chinese Medical Association emphasized that acute rejection (AR) within one year after organ transplantation is not only an early transplant. The main reason for the “lost” substance is also a key predictor of long-term graft survival. Studies have shown that the half-life of grafts that did not occur in AR patients within 1 year after transplantation was twice that of patients with AR (17.9 years and 8.8 years, respectively). The immune induction therapy can effectively reduce the incidence of AR after organ transplantation. "In addition, the use of such immunosuppressants can also reduce the administration of CNI (calcineurin inhibitors, such as CsA, FK506, etc.), thereby reducing its toxic effects on kidney transplants; at the same time, early hormone removal after transplantation can be achieved. , Or even no hormone program. Studies have shown that antibody-mediated induction therapy combined with these programs does not increase the incidence of acute rejection and maintain a higher human kidney survival rate."

"There are many cells involved in acute rejection after transplantation, and T cell activation is the central link of acute rejection." Key Laboratory of Organ Transplantation of Ministry of Education and Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology and Academic Committee of the Ministry of Health Organ Transplantation Key Laboratory Professor Chen Shi, director of the Fourth and Fifth Committee of the Chinese Medical Association Organ Transplantation Association, pointed out: "Antibody induction therapy can prevent and treat acute rejection by preventing the activation and proliferation of T cells."

"In KDIGO, a guideline for the improvement of foreign authoritative nephropathy, anti-CD25 monoclonal antibodies (interleukin 2 receptor antagonists) have been recommended as the first-line agents for induction therapy after transplantation." Deputy Director of the Organ Transplantation Society of the Chinese Medical Association, Professor Chen Zhonghua, member of the Asian Transplant Medical Association and member of the International Organ Transplantation Society added.

Professor Zhu Tongyu, vice president of Zhongshan Hospital of Fudan University, director of the Shanghai Organ Transplantation Key Laboratory and member of the Organ Transplantation Committee of the Chinese Medical Association, said: “A large number of clinical trials have confirmed that after the addition of enkephalin to the basic immunosuppressive regimen, kidney transplantation The incidence of acute rejection was reduced by 43.7% in the last 3 months, and the incidence of acute rejection was reduced by 40.2% at 6 months; the 1-year survival rate of the patient's kidney was 100% and 99.46%, respectively; Renal function has a certain recovery effect, patients have a very significant decrease in serum creatinine 1 week after transplantation, and more than 50% of patients have normal serum creatinine within 1 week.In addition, the test results also show that Kenipare is improving. The effect of anti-acute rejection does not increase the incidence of infection and tumor incidence in organ transplant recipients, and rarely leads to the production of neutralizing antibodies.Enzyme may not increase the use of cyclosporine A/FK506, mycophenolate mofetil The toxicity caused by immunosuppressive agents such as corticosteroids has good safety."